Recent Press Releases

Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 26, 2014

Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris

LAVAL, Quebec, Nov. 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration...

Drug recommended to help cut drink dependence

NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink. In England in 2012/13, there were around 1.2 million hospital admissions due...

BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR SELINCRO(r)

TURKU, Finland, Nov. 26, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology...

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo

THOUSAND OAKS, Calif. and LON

Salix Pharmaceuticals Announces Plan to Augment Board of Directors

Salix Pharmaceuticals Announces Plan to Augment Board of Directors November 24, 2014 04:01 PM Eastern Standard Time RALEIGH, N.C.--()--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)...

European Commission Approves Trulicity® (dulaglutide) Solution for Injection, Lilly's Once-Weekly, Ready-to-Use Type 2 Diabetes Treatment

European Commission Approves Trulicity® (dulaglutide) Solution for Injection, Lilly's Once-Weekly, Ready-to-Use Type 2 Diabetes Treatment - Trulicity, a glucagon-like peptide-1 (GLP-1)...

Novo Nordisk A/S: Changes in Novo Nordisk's Executive Management

BAGSVAERD, Denmark, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of...

Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 24, 2014

Ulf Wiinberg resigns as CEO of Lundbeck

Valby, Copenhagen, 2014-11-24 08:56 CET (GLOBE NEWSWIRE) -- Ulf Wiinberg has informed Lundbeck's Board of Directors that he is resigning as Chief Executive Officer with immediate effect ...

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties

The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock,...

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

$200+ Million Investment to Support Company's Maturing Biologics Pipeline FREDERICK, Md.--(BUSINESS WIRE)--AstraZeneca today announced plans to expand its biologics manufacturing center in...

European CHMP Adopts Positive Opinion for Genzyme's Cerdelga® (eliglustat) Capsules

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...

No consistent evidence of an increased risk of heart problems with testosterone medicines

European Medicines Agency - The CMDh, a regulatory body representing EU Member States, has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with...

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

• Phase III INPULSIS® trials showed that nintedanib* slows disease progression in a broad range of IPF patient types** with a 50% reduction in the decline of lung function •...

Spherix Comments on Pending Settlement Between Cisco and Rockstar Consortium

Spherix Litigation Against Cisco Continues On Patents Acquired from Rockstar Consortium

BETHESDA, Md., Nov.

Purdue Pharma L.P. Receives FDA Approval for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties

Purdue Pharma L.P. Receives FDA Approval for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties Stamford,...

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties For Immediate Release: Nov. 20, 2014 Media Inquiries: Jeff Ventura, 301-796-7567,...